Viewing Study NCT01719432


Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2025-12-29 @ 1:01 PM
Study NCT ID: NCT01719432
Status: COMPLETED
Last Update Posted: 2020-12-17
First Post: 2012-10-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of Body Mass on Filgrastim Pharmacokinetics
Sponsor: Aaron Cumpston, PharmD, BCOP
Organization:

Study Overview

Official Title: Effect of Body Mass on Filgrastim Pharmacokinetics
Status: COMPLETED
Status Verified Date: 2020-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan.

Patients in this study will have blood draws once before they take Neupogen and 6 times after they take the Neuopen (for a total of 24 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: